Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3254 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Keita Hirai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan. Hauptthemen laut MEDLINE: Asthma, Cytochrome P-450 CYP3A, NLR Family, Pyrin Domain-Containing 3 Protein, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Inflammation decreases the activity of cytochrome P450 3A (CYP3A). Nucleotide‐binding oligomerization domain (NOD)‐like receptor family pyrin domain containing 3 (NLRP3) is responsible for regulating the inflammatory response, and its genetic polymorphisms have been linked to inflammatory diseases such as asthma. However, there have been few studies on the effect of NLRP3 on CYP3A activity. We aimed to investigate the association between polymorphisms in the NLRP3 gene and plasma 4β‐hydroxycholesterol (4βOHC), an endogenous marker of CYP3A activity, in patients with asthma. In this observational study including 152 adult asthma patients, we analyzed 10 NLRP3 gene single‐nucleotide polymorphisms (SNPs). Plasma 4βOHC levels were measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS). The results showed that five SNPs were associated with significantly lower plasma 4βOHC concentrations. Among these SNPs, rs3806265, rs4612666, rs1539019, and rs10733112 contributed to a significant increase in plasma IL‐6 concentrations. Moreover, a multivariate regression model showed that the rs3806265 TT, rs4612666 CC, rs1539019 AA, and rs10733112 TT genotypes were significant factors for decreased plasma 4βOHC, even after including patient background factors and CYP3A5 *3 (rs776746) gene polymorphisms as covariates. These results were also observed when plasma 4βOHC concentrations were corrected for cholesterol levels. We conclude that NLRP3 gene polymorphisms are involved in increasing plasma IL‐6 concentrations and decreasing plasma 4βOHC concentrations in patients with asthma. Therefore, NLRP3 gene polymorphisms may be a predictive marker of CYP3A activity in inflammatory diseases such as asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology & Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
- Department of Pharmacy, Shinshu University Hospital, Nagano, Japan.
- Department of Clinical Pharmacology and Therapeutics, Shinshu University Graduate School of Medicine, Nagano, Japan.
- Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
- Laboratory of Clinical Pharmacogenomics, Shizuoka General Hospital, Shizuoka, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Hirai, K., Kimura, T., Suzuki, Y., Shimoshikiryo, T., Shirai, T., & Itoh, K. (2024). Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3254
Vancouver
Hirai K, Kimura T, Suzuki Y, Shimoshikiryo T, Shirai T, Itoh K. Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3254
BibTeX
@article{Hirai2024,
author = {Hirai, Keita and Kimura, Tomoki and Suzuki, Yuya and Shimoshikiryo, Takayuki and Shirai, Toshihiro and Itoh, Kunihiko},
title = {Gene Polymorphisms of NLRP3 Associated With Plasma Levels of 4β‐Hydroxycholesterol, an Endogenous Marker of CYP3A Activity, in Patients With Asthma},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3254}
}
EUVIMED